ArticleJHLT open2026
Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric heart recipients were associated with impairment of the immune system - a multicenter study from Sweden.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Posttransplant lymphoproliferative disorder (PTLD) is a potentially lethal complication after pediatric heart transplantation (PHT). We have previously reported an association between PTLD and (1) sternotomy during infancy, (2) mismatch concerning Epstein-Barr virus infection, (3) hypoplastic left ventricle and (4) surgically palliated congenital heart disease (CHD) as transplant indication versus cardiomyopathy (CMP). To explore whether there were significant differences in immunological profiles between the identified risk groups for PTLD and the rest of pediatric heart recipients. Methods: Data was partially collected as registry data from the previous study concerning PHT, PKT and HC 7. We then added clinical data and prospectively collected blood samples from additional PHT subjects from the 3 Swedish tertiary centers performing long-term follow-up after PHT. Blood samples were collected after transplantation (mean time 4.6 years, range 0.2-14.7 years) and were analyzed for immunophenotyping of T- and B-lymphocyte subpopulations and monocytes by flow cytometry, and T-cell receptor excision circles (TREC). Results: A total of 76 PHT subjects were included. Thirty-eight had undergone thymus excision during infancy and 22 had hypoplastic left ventricle. The transplant indication was CHD in 36 and CMP in 40 children. The immune profiles of the identified risk groups for PTLD were characterized by low numbers of TREC, naïve CD4+, naïve CD8+, naïve recent thymic emigrants (RTE) and among patients with CHD low numbers of T-helper cells (Th). In addition, the relative proportions of naïve cells were low. Conclusions: The identified PTLD risk groups demonstrated significant impairment in the immune system, a pattern consistent with immune dysfunction and features of immunological aging, both of which are conditions known to increase the risk of developing PTLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.